首页> 外文期刊>Research journal of pharmacy and technology >Conception and Evaluation of Extended Release Multiparticulate System of Milnacipran Hydrochloride
【24h】

Conception and Evaluation of Extended Release Multiparticulate System of Milnacipran Hydrochloride

机译:盐酸米那普仑缓释多颗粒系统的概念与评价

获取原文
获取原文并翻译 | 示例

摘要

Milnacipran HC1 is a selective norepinephrine and serotonin reuptake inhibitor well used drug for the treatment of depression and fibromyalgia. Milnacipran HC1 belongs to biopharmaceutical class I having short elimination half-life. Milnacipran HC1 recommended immediate release [IR] dose 50mg twice a day associated with frequent dosing which cause side effects, lack of patient compliance and discontinuation of therapy. To overcome such problems, the aim of the present study was to design novel once a day extended release multiparticulate system of Milnacipran HC1 using Fluidized bed processor wurster coating technique. To achieve the goal, drug solution layering was done on seal coated #25 - 30 non pareil sugar spheres followed by release controlling polymer coating of Ethyl cellulose and Hydroxypropyl methyl Cellulose in the ratio 90:10 respectively. In vitro dissolution study of 10, 12, and 14% release controlling polymer coated pellets was carried in distilled water using USP type II dissolution apparatus with sinkers. Ratio of hydrophobic to hydrophilic polymer and level of coating have highest effect on drug release. Milnacipran HC1 release extended for longer duration as percent of release controlling polymer coating increased. The release kinetics was explored and explained with zero order, first order, Higuchi and Korsmeyer equations. The drug release from pellets has no significant effect of pH of dissolution medium.
机译:Milnacipran HC1是选择性去甲肾上腺素和5-羟色胺再摄取抑制剂,广泛用于治疗抑郁症和纤维肌痛。 Milnacipran HC1属于具有消灭半衰期短的I类生物制药。 Milnacipran HC1建议每天两次两次立即释放[IR]剂量,剂量为50mg,经常服用会引起副作用,缺乏患者依从性并终止治疗。为了克服这些问题,本研究的目的是使用流化床处理器仓促包衣技术设计每日一次的新型Milnacipran HC1缓释多颗粒系统。为了实现该目标,在密封包封的#25-30非平行糖球上进行药物溶液分层,然后分别以90:10的比例控制乙基纤维素和羟丙基甲基纤维素的聚合物释放涂层。使用具有沉降片的USP II型溶出度仪在蒸馏水中进行10%,12%和14%释放控制的聚合物包衣小丸的体外溶出度研究。疏水性与亲水性聚合物的比例和包衣水平对药物释放有最大影响。 Milnacipran HC1的释放延长了更长的持续时间,因为释放控制聚合物涂层的百分比增加。探索了释放动力学,并用零阶,一阶,Higuchi和Korsmeyer方程进行了解释。从药丸中释放的药物对溶出介质的pH值没有显着影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号